Drug profile · INN
pegulicianine acetate
LUMISIGHT
pegulicianine acetate (LUMISIGHT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — pegulicianine acetate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
pegulicianine acetate (LUMISIGHT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Diagnostic agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is pegulicianine acetate?
pegulicianine acetate (LUMISIGHT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for pegulicianine acetate?
LUMISIGHT is a marketed brand name for pegulicianine acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegulicianine acetate?
pegulicianine acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.